161 research outputs found
PML as a potential predictive factor of oxaliplatin/fluoropyrimidine-based first line chemotherapy efficacy in colorectal cancer patients
PML regulates a wide range of pathways involved in tumorigenesis, such as apoptosis, which is also one of the main mechanisms through which oxaliplatin and fluoropyrimidine exert their antineoplastic activity. The present study aims to investigate PML expression as a predictive factor of oxaliplatin/fluoropyrimidine therapy efficacy.
EXPERIMENTAL DESIGN:
74 metastatic colorectal cancer patients who received oxaliplatin/floropyrimidine-based first line therapy have been included in this retrospective study. PML expression was assessed by immunohistochemistry.
RESULTS:
PML down-regulation was detected in 39 (52.7%) patients (14 complete and 25 partial PML loss). RR was significantly lower (25.6%) in patients with PML down-regulation than in patients with preserved PML expression (60%) (P\u2009=\u20090.006). Median TTP was 5.5 months when PML was down-regulated versus 11.9 months in case of preserved PML expression (P\u2009<\u20090.0001). A statistical significant difference was also detected in OS (15.6 and 24.5 months respectively, P\u2009=\u20090.003). The impact of PML down-regulation on TTP and OS was statistically significant also in a multivariate model.
CONCLUSIONS:
This study represents the first evidence of a possible correlation between PML protein expression and outcome of metastatic colorectal cancer patients treated with oxaliplatin/fluoropyrimidine-based first line therapy
Promyelocytic leukemia (PML) gene expression is a prognostic factor in ampullary cancer patients
BACKGROUND:
Promyelocytic leukemia (PML) tumor suppressor gene plays a key role in acute PML pathogenesis but its involvement in pathogenesis and prognosis of solid cancers has not been defined yet.
PATIENTS AND METHODS:
In all, 62 ampullary adenocarcinoma patients who underwent curative surgery between 1996 and 2005 were included. Expression analysis of PML was carried out by immunohistochemical staining and correlated with disease-free survival (DFS) and overall survival (OS).
RESULTS:
In 24 tumor specimens (38.7%), PML was classified as absent, in 16 (25.8%) as focally expressed and in 22 (35.5%) as diffusely expressed. By univariate analysis, DFS was significantly influenced by pathological T stage (P=0.03), lymph nodal involvement (P=0.002), and PML expression (P=0.001). DFS in patients without PML expression was 28.0 months versus 45.1 and 75.5 for patients with focal and diffuse expression, respectively. OS in the group of patients without PML expression, with focal expression, and with diffuse expression was 40, 48, and 77 months, respectively (P=0.002). By a multivariate analysis, PML expression was the strongest prognostic factor for DFS (P=0.003) and the only statically significant prognostic factor for OS (P=0.009).
CONCLUSIONS: Our preliminary data suggest PML as a novel prognostic tool for ampullary cancer patients
Supporting XML Security Models Using Relational Databases: A Vision
As the secure distribution and sharing of information over the World Wide Web becomes increasingly important, the needs for flexible and e#cient support of access control systems naturally arise. Since the eXtensible Markup Language (XML) is emerging as the format of the Internet era for storing and exchanging information, there have been, recently, many proposals to extend the XML model to incorporate security aspects. To the lesser or greater extent, however, such proposals neglect the fact that the data for XML documents will most likely reside in relational databases, and consequently do not utilize various security models proposed for and implemented in relational databases
Preoperative Risk Stratification in Patients Undergoing Elective Infrarenal Aortic Aneurysm Surgery: Evaluation of Five Risk Scoring Methods
n/
- …